IMS2186

IMS2186 is an anti-choroidal neovascularization (CNV) agent that inhibits angiogenesis upstream of VEGF. IMS2186 can arrest cancer cell cycle in G2/M phase, thus exerting anti-proliferation and anti-angiogenesis effects. IMS2186 has no intraocular toxicity and reduces the amount of eye leakage and diseased cells[1].

Product Specifications

CAS Number

[1031206-36-6]

UNSPSC

12352005

Hazard Statement

H410

Target

VEGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/ims2186.html

Purity

99.96

Solubility

DMSO : 66.67 mg/mL (ultrasonic)

Smiles

O=C1/C(COC2=CC=C(C)C=C12)=C/C3=CC=C(OC)C(O)=C3

Molecular Formula

C18H16O4

Molecular Weight

296.32

Precautions

H410

References & Citations

[1]Falkenstein IA, et al. Toxicity and intraocular properties of a novel long-acting anti-proliferative and anti-angiogenic compound IMS2186. Curr Eye Res. 2008 Jul;33 (7) :599-609. |[2]DeNiro M, et al. Reversal of retinal vascular changes associated with ocular neovascularization by small molecules: progress toward identifying molecular targets for therapeutic intervention[J]. VASCULAR, 2011, 15: P17.